Bayer Accelerates Six New Startups

BayerChanging the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies from Canada, Germany, Israel, Spain, the United Kingdom and the United States came out ahead of more than 1,800 competitors from 100 countries. They now have 100 days in which to intensively drive the further development of their products and solutions with expertise and investment from Bayer. The company will provide them with offices in Berlin, pharmaceutical executives and industry experts as mentors and EUR 50,000 in funding for each project.

"Digital solutions are essential to driving innovation in an evolving healthcare environment. Bayer is seeking to apply them across the pharmaceutical value chain in order to detect diseases at an earlier stage, to develop medicines faster, and to deliver individual treatments with a meaningful outcome for patients. In this endeavor, we benefit immensely from collaborations and the exchange of knowledge and skills with innovative startups," explains Dieter Weinand, Member of the Board of Management of Bayer AG and head of the Pharmaceuticals Division. Cooperation with startups is an integral part of Bayer's overall digital transformation. The company is driving a Group-wide initiative called "Advancing Digital" to foster innovative solutions in healthcare and agriculture.

Six years ago, Bayer started cooperating with startups in the healthcare sector through the G4A program headed by Eugene Borukhovich. "It's incredible to see the tremendous impact that some of our startups have had in the industry. I’m impressed to see the maturity and significance of their innovative solutions. Through the Accelerator program, I'm convinced we will be able to make a significant contribution to truly change the experience of health as we know it. We will continue to put people at the center of their health and care every single day," Borukhovich says.

The startups that have applied are developing digital solutions that cover the entire value chain within healthcare. Also this year, a patient jury was asked to rank startups according to the impact that their solutions would have on patient experience.

This year's winners are:

  • Agamon (Israel, GB): A healthcare intelligence platform that can be used to compile and structure health-related data from various sources in order to derive new information. www.agamon.io
  • Cyclica (Canada): A cloud platform that aims to use artificial intelligence and biophysics to accelerate drug development. www.cyclicarx.com
  • KinAptic (USA): An accelerated learning system for VR stroke rehabilitation using electric stimulation that analyzes and detects neural signals to stimulate nerves in stroke patients. www.kinaptic.com
  • OME (GB): Personalized health coaching that uses extensive data analyses to compile individualized health programs (nutrition, sleep, physical activity) in order to prevent disease. www.ome.health
  • S-There Technologies (Spain): A smart device that analyzes health data through urine in the toilet and gives patients insights into their health. https://s-there.com
  • Zencorlabs (Germany): A smartphone software and device that uses artificial intelligence to warn patients of heart failure. www.zencorlabs.com

About G4A

G4A is the name under which Bayer combines the Group's digital-health initiatives. These include the identification of new technologies, business models and market trends, and cooperation with startups. The core of this collaboration is the Accelerator program under which Bayer provides startups with offices in Berlin for 100 days, experienced managers as coaches and EUR 50,000 in funding for each project. At the same time, Bayer's Dealmaker program seeks to identify more mature startups capable of working on specific health-related challenges. Bayer launched G4A in 2013, originally with the aim of promoting app development in healthcare (hence the name Grants4Apps). Today Bayer actively promotes G4A in more than 13 countries worldwide to develop and accelerate new collaborations in digital health.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of 35.0 billion euros. Capital expenditures amounted to 2.4 billion euros, R&D expenses to 4.5 billion euros.

Most Popular Now

AI Identifies Anti-Aging Drug Candidates…

A new publication in the May issue of Nature Aging by researchers from Integrated Biosciences, a biotechnology company combining synthetic biology and machine learning to target aging, demonstrates the power...

AI could Improve Heart Attack Diagnosis …

An algorithm developed using artificial intelligence (AI) could soon be used by doctors to diagnose heart attacks with better speed and accuracy than ever before, according to new research from...

AI Predicts Future Pancreatic Cancer

An artificial intelligence (AI) tool has successfully identified people at the highest risk for pancreatic cancer up to three years before diagnosis using solely the patients’ medical records, according to...

New Algorithm can Predict Diabetic Kidne…

Researchers from Sanford Burnham Prebys and the Chinese University of Hong Kong have developed a computational approach to predict whether a person with type 2 diabetes will develop kidney disease...

AI Voice Coach Shows Promise in Depressi…

Artificial intelligence (AI) could be a useful tool in mental health treatment, according to the results of a new pilot study led by University of Illinois Chicago researchers. The study...

AI could Run a Million Microbial Experim…

An artificial intelligence (AI) system enables robots to conduct autonomous scientific experiments - as many as 10,000 per day - potentially driving a drastic leap forward in the pace of...

Scientists develop AI tool to predict Pa…

Scientists from UNSW Sydney with collaborators at Boston University have developed a tool that shows early promise in detecting Parkinson’s disease years before the first symptoms start appearing. In research published...

Better than Humans: AI in Intensive Care…

In the future, artificial intelligence (AI) will play an important role in medicine. In diagnostics, successful tests have already been performed: for example, the computer can learn to categorise images...

Could Online Gaming Social Networks Have…

For millions of Americans playing some type of video game is a daily occurrence. Games can be a welcome form of entertainment and relaxation for many, and the internet can...

ChatGPT Passes Radiology Board Exam

The latest version of ChatGPT passed a radiology board-style exam, highlighting the potential of large language models but also revealing limitations that hinder reliability, according to two new research studies...

Siemens Healthineers Opens State-of-the-…

Siemens Healthineers has opened its new Education & Development Center (EDC) in Erlangen. The open-plan building offers space for the currently 240 trainees and integrated degree program participants in Erlangen...

Siemens Healthineers Invests 80 Million …

Siemens Healthineers is building a new factory in Forchheim for the cultivation of crystals for semiconductor production. The total investment amounts to 80 million euros. The new factory is expected...